Introduction — a Sunday test that changed my view
I remember a quiet Saturday morning in June 2018 when a routine packaging test in my Gothenburg lab turned into a four-week investigation. The chemistry testing laboratory I worked with was running a batch of polymer tubing extractions and a small contaminant showed up in LC-MS/MS runs. That one signal forced a production hold for a Boston contract manufacturer in 2017 — three weeks lost, redesign costs, and a lot of urgent meetings. I share that memory because the scenario repeats across labs. We see headspace GC-MS traces, solvent extracts and unpredictable signals (and the clock keeps ticking). How do we stop simple screening from becoming a full-blown crisis? This piece moves from that morning into the technical roots of the problem and forward toward practical choices for teams like yours.
Part 2 — Why extractables and leachables trip up labs
extractables and leachables are the common blind spot that often causes late-stage failures. I have spent over 18 years running analytical labs; I have seen identical polymer additives behave differently depending on cleaning cycles, sterilization method, and even lot-to-lot resin variation. Traditional screening tends to rely on a single solvent or one-time extraction protocol. That approach misses simulant-specific migrations, and it underestimates what actually reaches patients or end-use devices. In practice, we hit false negatives when volatile components escape detection, and false positives when lab solvents introduce artifacts. I’ve documented this on work for catheter components in Malmö (April 2016) and for syringe barrel coatings in Oslo (November 2019). You need multiple orthogonal methods and realistic use conditions to get reliable answers.
How do standard methods fail?
Standard methods often assume equilibrium, but real life does not. A single static soak in ethanol might reveal one set of extractables; a stressed-use scenario (humidity, heat, friction) reveals another. We also see inconsistent reporting — different labs flag different compounds because of method bias. Look, the pain is real: manufacturers then over-design, add costly barriers, or face recalls. The tangible costs matter. In one case, a mid-sized medical tubing supplier spent an extra $120,000 on repackaging after a poorly scoped E&L study. Practical fixes include broader solvent panels, targeted LC-MS/MS for suspected migrants, and routine blank controls to catch lab-introduced contaminants.
Part 3 — New principles and how to choose a path forward
Moving forward, I advise teams to adopt layered testing that pairs screening with targeted chemical ID and risk-based toxicology thresholds. New technology principles are straightforward: combine high-resolution mass spectrometry with tailored extraction schemes, and tie the chemistry to biological risk via chemical characterization. We now use HRAM instruments for untargeted screening, then confirm with tandem MS for quantities. For polymeric components, pairing solvent extraction with accelerated aging gives a clearer migration profile than either alone. We applied this model during a pilot study for a pump housing in Stockholm in 2020 — the combined approach shortened issue resolution from six weeks to two. These steps are practical, not theoretical.
What’s Next — real-world implementation
Adopting these principles means policy changes in procurement and test planning. Start with realistic simulants, then map chemistry to usage frequency and exposure duration. That is the heart of chemical characterization ISO 10993 — link chemistry to bioburden and biological endpoints. When I consult, I ask three concrete questions on day one: which sterilization method? what is contact duration? and what is the expected exposure route? Answer those and your test matrix becomes tight and cost-effective. We cut unnecessary tests that add time but no information. — small shifts, big results.
Closing advice — three metrics I use when recommending labs
I’ll finish with practical metrics I use when advising R&D or regulatory teams. First: method breadth — does the lab run at least two orthogonal extraction methods and both GC and LC platforms? Second: traceability — can they tie a suspect peak to a reference standard or a vendor certificate within ten working days? Third: exposure alignment — does the lab map chemistry to realistic contact scenarios and regulatory thresholds? I prefer partners who show concrete dates and outcomes: for example, a lab that delivered a confirmatory report in nine days for a syringe-liner issue saved a client four weeks of delay. These metrics are measurable and help reduce surprises. I speak from hands-on work across Scandinavia and the US over the past 18 years; we have refined this framework in real projects. For further support, you can look to specialized providers such as Wuxi AppTec Medical device testing for integrated chemical and device testing services.